0001209191-18-008609.txt : 20180208
0001209191-18-008609.hdr.sgml : 20180208
20180208203922
ACCESSION NUMBER: 0001209191-18-008609
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180206
FILED AS OF DATE: 20180208
DATE AS OF CHANGE: 20180208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Amanullah Ashraf
CENTRAL INDEX KEY: 0001670631
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37378
FILM NUMBER: 18587360
MAIL ADDRESS:
STREET 1: C/O ATYR PHARMA, INC.
STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: aTYR PHARMA INC
CENTRAL INDEX KEY: 0001339970
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203435077
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-731-8389
MAIL ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-06
0
0001339970
aTYR PHARMA INC
LIFE
0001670631
Amanullah Ashraf
3545 JOHN HOPKINS COURT, SUITE #250
SAN DIEGO
CA
92121
0
1
0
0
See Remarks
Common Stock
2018-02-07
4
M
0
3334
0.00
A
3334
D
Common Stock
2018-02-08
4
S
0
1402
3.40
D
1932
D
Employee Stock Option (right to buy)
3.30
2018-02-06
4
A
0
100000
0.00
A
2028-02-06
Common Stock
100000
100000
D
Restricted Stock Units
0.00
2018-02-07
4
M
0
3334
0.00
D
Common Stock
3334
6666
D
Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017.
Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 7, 2017.
The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
The RSU grant vests as to one-third (1/3) of the total number of units on each one year anniversary of the grant commencing on February 7, 2018.
Senior Vice President, Biologics Development and Manufacturing
Nancy D. Krueger, Attorney-In-Fact
2018-02-08